CLASS ACTION UPDATE for CBL, HRTX and PVTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 25, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

CBL & Associates Properties, Inc (NYSE: CBL)

Class Period: November 8, 2017 - March 26, 2019
Lead Plaintiff Deadline : July 16, 2019
Join the action: https://www.zlk.com/pslra-1/cbl-associates-properties-inc-loss-form?prid=2055&wire=1

Allegations: CBL & Associates Properties, Inc made materially false and/or misleading statements throughout the class period and/or failed to disclose that: the Company was the target of a class action suit that could result in tens of millions or even hundreds of millions of dollars in liability. The Complaint further alleges that Defendants completely ignored their disclosure obligation, motivated by a desire to avoid bad publicity surrounding their dishonest nature and their dishonest conduct. When the truth was revealed, CBL shares materially declined in price, injuring the class.

To learn more about the CBL & Associates Properties, Inc class action contact jlevi@levikorsinsky.com.

Heron Therapeutics, Inc. (NASDAQ: HRTX)

Class Period: October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
Join the action: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=2055&wire=1

Allegations: Heron Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011; and (iii) as a result, Heron's public statements were materially false and misleading at all relevant times.

To learn more about the Heron Therapeutics, Inc. class action contact jlevi@levikorsinsky.com.

Pivotal Software, Inc. (NYSE: PVTL)

Class Period: investors who purchased common stock pursuant or traceable to the April 2018 initial public offering and/or Pivotal securities between April 24, 2018 and June 4, 2019.
Lead Plaintiff Deadline : August 19, 2019
Join the action: https://www.zlk.com/pslra-1/pivotal-software-inc-loss-form?prid=2055&wire=1

Allegations: During the class period, Pivotal Software, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry's sentiment shifted away from Pivotal's principal products because the Company's products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Pivotal Software, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP